Black Diamond Therapeutics (BDTX) Income from Continuing Operations (2018 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Income from Continuing Operations came in at 11375000.0 in Q1 2026, down 121.06% YoY from 54016000.0 in Q1 2025, and up 35.24% on a QoQ basis from 17565000.0 in Q4 2025.
Black Diamond Therapeutics (BDTX) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 9 years of Income from Continuing Operations data on file, last reported at 11375000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 121.06% year-over-year to 11375000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 57151000.0 (down 43.98% YoY) and the FY2025 annual result came in at 107640000.0, up 47.28% from the prior year.
- Income from Continuing Operations climbed to 11375000.0 in Q1 2026, from 17565000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 54016000.0 in Q1 2025 to a low of 57265000.0 in Q3 2022.
- A 5-year average of 22501235.29 and a median of 21990000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations soared 361.09% — and 2026, when it tumbled 121.06%.
- Tracing BDTX's Income from Continuing Operations over 5 years: stood at 22226000.0 in 2022, then gained by 2.77% to 21611000.0 in 2023, then increased by 12.92% to 18819000.0 in 2024, then increased by 6.66% to 17565000.0 in 2025, then jumped by 35.24% to 11375000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 11375000.0 (Q1 2026), 17565000.0 (Q4 2025), and 15325000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | -11.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.26 Mn |
| Mar 31, 2026 | -11.38 Mn |
| Dec 31, 2025 | -17.57 Mn |
| Sep 30, 2025 | -15.33 Mn |
| Jun 30, 2025 | -12.89 Mn |
| Mar 31, 2025 | 54.02 Mn |
| Dec 31, 2024 | -18.82 Mn |
| Sep 30, 2024 | -24.98 Mn |
| Jun 30, 2024 | -49.92 Mn |
| Mar 31, 2024 | -20.69 Mn |
| Dec 31, 2023 | -21.61 Mn |
| Sep 30, 2023 | -55.06 Mn |
| Jun 30, 2023 | -30.81 Mn |
| Mar 31, 2023 | -21.99 Mn |
| Dec 31, 2022 | -22.23 Mn |
| Sep 30, 2022 | -57.27 Mn |
| Jun 30, 2022 | -30.05 Mn |
| Mar 31, 2022 | -25.98 Mn |
| Dec 31, 2021 | -26.10 Mn |
| Sep 30, 2021 | -43.00 Mn |